HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Prazosin

HCID 4893
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
19216-56-9
Standard SMILES
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
Molecular formula
C19H21N5O4
Average molar mass
383.4 g/mol
Monoisotopic mass
383.15935417

Overview

Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of furans, a member of piperazines, a monocarboxylic acid amide, an aromatic ether and a member of quinazolines.

Names & identifiers

Preferred name
Prazosin
IUPAC
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
English name
Prazosin
Molecular formula
C19H21N5O4
Molecular weight
383.4

Names & synonyms

prazosin19216-56-9FurazosinPrazosinePrazosinaPrazosinum1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazolineDTXSID4049082Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-XM03YJ541DCP-122991
Show more names
pressinminipressAKOS B020009PrazosinBaseTerazosin-010Prazosin USP/EP/BPART-CHEM-BB B020009
CHEBI:8364DTXCID0029008Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine2-[4-(2-Furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)-furan-2-ylmethanone[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-furan-2-ylmethanone2-(4-((furan-2-yl)carbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine

Database identifiers

CAS
19216-56-9
PubChem CID
4893
DTXSID
DTXSID4049082
ChEMBL
CHEMBL2
ChEBI
CHEBI:8364
UNII
XM03YJ541D
EC Number
242-885-8
Nikkaji
J10.000E

Properties

Computed structural properties

XLogP
2
Topological polar surface area
107 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
8
Rotatable bonds
4
Heavy atoms
28
Formal charge
0
Complexity
544

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 items

1.3

1.9

Solubility6.93e-01 g/L
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Adrenergic alpha-Antagonists; Antihypertensive Agents

Pharmaceuticals

Melting Point · 2 items

277-280

279 °C

Physical DescriptionSolid
Dissociation Constants6.54
Collision Cross Section · 2 items

192.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

186.41 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
278 · 278-280°C
Boiling point
510.33 °C · 510.33°C (rough estimate)
Density
1.3275 · 1.3275 (rough estimate)
refractive index
1.76 · 1.7600 (estimate)
storage temp.
2 · 2-8°C
solubility
DMSO (Slightly), Methanol (Slightly, Heated)
form
Solid
pka
6.54 · pKa 6.54(50% EtOH) (Uncertain)
color
White to Off-White
Water Solubility
3.2 mg/L · 3.2mg/L(22.5 ºC)
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
SMILES
C(N1CCN(C2=NC(N)=C3C(=N2)C=C(OC)C(OC)=C3)CC1)(C1=CC=CO1)=O
FDA UNII
3 YJ541D · XM03YJ541D
ATC code
2 CA01 · C02CA01
Comptox DTXSID
4049082 · DTXSID4049082
Protein binding
97 % · 97%
Excreted unchanged in urine
10 % · <10%
Volume of distribution
1.2 · 1.2-1.5(L/kg)
Biological half-life
2 · 2-4 / Unchanged
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
335 · H335-H319-H315
Precautionary statements
264 · P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Other Safety InformationIMAP assessments - Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (50%)

Toxicology

Hepatotoxicity · 1 item

Prazosin has been associated with a low rate of serum aminotransferase elevations that in controlled trials was no higher than with placebo therapy. These elevations were transient and did not require dose modification. No instances of clinically apparent acute liver injury due to prazosin have been published in the literature, but reports of cholestatic hepatitis have been received by the sponsor. Among the alpha adrenergic receptor antagonists, the most frequently implicated agent in causing liver injury has been alfuzosin with only single, and not well documented cases linked to other alpha blockers. Thus, acute symptomatic liver injury due to prazosin is quite rare, and severe hepatotoxicity must be exceeding rare, if it occurs at all.

Adverse EffectsSerious Adverse Effects
Toxicity SummaryThere is no direct toxicity with this medication. High doses and overdoses could lead to hypotension, and patients should be supported clinically with volume resuscitation if necessary or pressor support.
Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

prazosin

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H335-H319-H315
Precautionary statements
P264-P280-P305+P351+P338-P337+P313P-P264-P280-P302+P352-P321-P332+P313-P362

Chemistry & industry

Pharmacology

ATC Code · 3 items

C02CA01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingHighly bound to proteins with 97% binding to albumin and alpha 1-acid glycoprotein. Prazosin is thought to be mostly (about 80-90%) bound to albumin.
Pharmacodynamics · 1 item

**Effects on blood pressure** The pharmacodynamic and therapeutic effect of this drug includes is a decrease in blood pressure as well as clinically significant decreases in cardiac output, heart rate, blood flow to the kidney, and glomerular filtration rate. The decrease in blood pressure may occur in both standing and supine positions. Many of the above effects are due to vasodilation of blood vessels caused by prazosin, resulting in decreased peripheral resistance,. Peripheral resistance refers to the level resistance of the blood vessels to blood that flows through them. As the blood vessels constrict (narrow), the resistance increases and as they dilate (widen), and peripheral resistance decreases, lowering blood pressure. **Effects on sleep disturbance related to post-traumatic stress disorder (PTSD)** Some studies have suggested that this drug improves sleep in patients suffering from insomnia related to nightmares and post-traumatic stress disorder, caused by hyperarousal. This effect likely occurs through the inhibition of adrenergic stimulation found in states of hyperarousal.

Mechanism of Action · 1 item

Alpha-adrenergic receptors are essential for the regulation of blood pressure in humans. Two types of alpha receptors, alpha 1 and alpha 2, both play a role in regulating blood pressure. Alpha-1 receptors are postsynaptic (located after the nerve junction, or space between a nerve fiber and target tissue). In this case, the target tissue is the vascular smooth muscle. These receptors, when activated, increase blood pressure. Prazosin inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation. Through blood vessel constriction by adrenergic receptor activation, epinephrine and norepinephrine normally act to increase blood pressure.

Biological Half-LifeThe plasma half-life is about 2-3 hours.
Metabolism/MetabolitesIn animals, prazosin hydrochloride is heavily metabolized. This occurs through liver demethylation and conjugation. Some studies in humans or human cells in vitro show similar prazosin metabolism.
FDA Pharmacological Classification · 6 items

XM03YJ541D

PRAZOSIN

Mechanisms of Action [MoA] - Adrenergic alpha-Antagonists

Established Pharmacologic Class [EPC] - alpha-Adrenergic Blocker

Prazosin is an alpha-Adrenergic Blocker. The mechanism of action of prazosin is as an Adrenergic alpha-Antagonist.

PRAZOSIN

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Absorption, Distribution and Excretion · 4 items

After administration of an oral dose, peak plasma concentrations are attained at approximately 3 hours. There is a linear association between the prazosin dose given and plasma concentration at steady state.

This drug is mainly excreted in the bile and the feces.

About 0.6 L/kg.

In patients with congestive heart failure, the clearance of this drug is decreased. Impairment of renal function does not have relevant effects on elimination.

Cellular LocationsExtracellular

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >10
Use ClassificationPharmaceuticals
Applications · 4 items

HistoryPrazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.According to FDA, in October 2025, New Jersey-based drugmaker Teva Pharmaceuticals USA and drug distributor Amerisource Health Services issued voluntary nationwide recalls of over half a million bottles of various strengths of prazosine capsules, which may include a cancer-causing chemical.

UsesPrazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output.

UsesPrazosin is used to treat average or moderate hypertension. Upon taking this drug, blood pressure drops without substantial changes in indicators of heart work, such as rate, coronary flow, and cardiac output. Prazosin is used for weak to moderate hypertension.

UsesAntihypertensive.

Upstream & downstream products

Upstream raw materials

1-(2-Furoyl)piperazineBenzonitrileAmmonia-ammonium chlorideIodomethaneThioureaAmmonia2-Furoyl chloride2-Chloro-4-amino-6,7-dimethoxyquinazolinePiperazine2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine

Downstream products

Bunazosin

Additional notes

DefinitionChEBI: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Related reactions

10 records
New reaction record
HRID 372680 reaction equation
HRID 372680As product
HRID 461331 reaction equation
HRID 461331As product
HRID 461336 reaction equation
HRID 461336As product
HRID 826660 reaction equation
HRID 826660As product
HRID 840093 reaction equation
HRID 840093As product
HRID 979728 reaction equation
HRID 979728As reactant
HRID 1576327 reaction equation
HRID 1576327As product
HRID 1580969 reaction equation
HRID 1580969As product
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes